



# Machine Learning Approaches for Comprehensive Analysis of Population Cancer Registry Data



**Ph.D Defense** 

Authored by Dídac Florensa Cazorla

Supervised by Pere Godoy Garcia Francesc Solsona Tehàs Jordi Mateo Fornés

Industrial supervision by Miquel Mesas Julió

19th April 2023







**1.**Motivation

**2.Introduction** 

**3.Hypotheses** 

**4.Objectives** 

5.Methodology (6 papers)

**6.**Conclusions and future research

















**Motivation** 



# RISK FACTORS AND LIFESTYLE DATABASE

# POPULATION CANCER REGISTRY DATABASE



















































## \* Introduction \* Population-based Cancer Registry (PBCR)

Universitat de Lleida

Salut/G











The registry was established in 2017 to retrospectively register new cases from 2012



This system allows to study the characteristic of Lleida. This population differs from other regions



The system is registering 90% of cases























# Introduction Pharmacology medicines

 Previous studies demonstrated the relationship between some medicines and cancer<sup>1</sup>.

• There is also prior evidence for a protective effect of some drugs. One such case is aspirin<sup>2</sup>.

• Aspirin is prescribed for preventing recurrent cardiovascular events and for relieving symptoms

of rheumatoid arthritis<sup>3</sup>.

<sup>1</sup>Friedman GD *et al*. Screening pharmaceuticals for possible carcinogenic effects: Initial positive results for drugs not previously screened. Cancer Causes Control. 2009;20(10):1821–35.
<sup>2</sup>Rothwell P.M. *et al*. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomized trials. The Lancet. 2010; 376 (9754); 1714-1750.

<sup>3</sup>Bibins-Domingo. *et al*. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine. 2016.















# **Artificial Intelligence (AI)**

Digital computer's ability to understand and perform tasks associated with intelligent beings.

# **AI** applications

- 1. Natural Language Process
- 2. Computer vision
- 3. Robotics
- 4. Machine Learning







### **Machine Learning**



# Supervised learning

It involves training a model to learn a function that maps input data to the correct output labels



# **Unsupervised learning**

Type of machine learning where the model is not given any labelled training data and is instead asked to learn patterns



# **Hypotheses**











**13456** To extract, integrate and assess external databases such as lifestyle and medicines prescriptions.

To develop a cloud platform to analyze cancer incidence.





To analyze associations between overweight, smoking and heavy alcohol use and Secondary Primary Cancer.

**5 6** To analyze the association between aspirin on some cancers.









Salut/ S Gestió de Serveis Sanitaris













| Registre de càncer de L | leida ≡   |                      |                            |            |           | 🗉 📍 Log out  |
|-------------------------|---|----------------------|----------------------------|------------|-----------|--------------|
| Buscar Q                | Incidence   |                      |                            |            |           |              |
| 🙆 Main menu             | Filtre  |                      |                            |            |           |              |
| N Incidence             | -   |                      | _                          |            |           |              |
| × Risk factors          | Tots  | -                    | E Analysis year            |            |           |              |
| <b>X</b> Mortality      |   |                      |                            |            |           |              |
|                         |   |                      |                            |            |           |              |
|                         | Incidence   |                      | Incidence table            |            |           |              |
|                         |   |                      | incluence table            |            |           |              |
|                         | Map Barplot   | _                    |                            |            | Buscar:   |              |
|                         | +   |                      | Region                     | Cases      | Incidence | ÷            |
|                         | - <u>_</u>  |                      | Alta Ribagorra             | 9          | 256       |              |
|                         |   |                      | Garrigues                  | 118        | 588       |              |
|                         |   |                      | Noguera                    | 222        | 557       |              |
|                         | locide to the second | nce (100.000 hab)    | Pallars Jussà              | 73         | 521       |              |
|                         |   | 00 - 200<br>00 - 100 | Pallars Sobirà             | 28         | 381       |              |
|                         | -   | 00 - 50<br>  - 50    | Pla d'Urgell               | 179        | 484       |              |
|                         |   | Leaflet              |                            |            | Enrere    | 1 2 Endavant |
|                         | Purchasi di da anno   |                      | Dimenida                   |            |           |              |
|                         | Evolucio de casos   |                      | Piramide                   |            |           |              |
|                         |   |                      | 95-99-                     |            |           | Gender       |
|                         | 2450  |                      | 90-94-<br>85-89-<br>80-84- |            |           | Female       |
|                         | 2400  |                      | 75-79-70-70-74-            |            |           | Male         |
|                         | 2330  |                      | 65-69-<br>60-64-           |            |           |              |
|                         | Ŭ 2250  |                      | 0 50-54-<br>45-49-         |            |           |              |
|                         | 2200  |                      | 40-44 -<br>35-39 -         |            |           |              |
|                         | 2150  |                      | 30-34-<br>25-29-<br>20-24- | - <b>-</b> |           |              |
|                         | 2100  |                      | 15-19-<br>10-14-           |            |           |              |
|                         | -<br>2012 2013 2014 2015  | 2016                 | 0-4-                       | 0          |           | _            |
|                         | Year  |                      |                            | Population |           |              |













Rural and urban areas differ in cancer incidence rates<sup>1</sup>

- In Lleida, approximately half of the population lives in rural areas
- Multiple Correspondence Analysis as a technique to explore associations between cancer incidence and sociodemographic information.



<sup>1</sup>Centers for Disease Control and Prevention. *Colorectal Cancer Incidence, United States—2003–2019.* USCS Data Brief, no. 33. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services: 2023.

Paper II





### Multiple Correspondence Analysis (MCA)

Paper II Methodology

1. To explore and visualize information contained on individuals described by categorical variables

2. The **contribution** enables us to consider how much influence a category has in determining to the entire set of the active category.

3. To evaluate the relationships between population, age and gender for each cancer.





**Paper II** MCA Associations











# **Colorectal cancer**

- Colorectal cancer is the highest incidence cancer in Lleida region for both genders
- Overweight, smoking or demographic information can be associated with the risk of colorectal cancer<sup>1</sup>

# **Non-supervised algorithms**

MCA to detect relations among large datasets and K-means to identify cluster of patients



<sup>1</sup>Safiri *et al*. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology. 2019; 4(12).



**Paper III** MCA and K-means





- Un-supervised learning algorithm used in data-mining and pattern recognition.
- The algorithm partitions the data set into K pre-defined distinct non-overlapping clusters where each data point belongs to only one group.

# Ф











| Cluster1       | Cluster 2        | Cluster 3        | Cluster 4        | Cluster 5        |
|----------------|------------------|------------------|------------------|------------------|
| Urban***       | Rural*           | Semi-<br>urban** | Urban***         | Semi-<br>urban** |
| Age >75        | Age 50-64        | Age >75          | Age 65-74        | Age 65-74        |
| Low income     | High<br>income   | Low<br>income    | Low income       | Low income       |
| Male           | Female           | Male             | Male             | Female           |
| Non-<br>smoker | Non-<br>smoker   | Non-<br>smoker   | Smoker           | Non-<br>smoker   |
| Overweight     | Normal<br>weight | Obesity          | Normal<br>weight | Overweight       |
| Alive          | Alive            | Death            | Alive            | Alive            |

\*< 2,000 inhabitants: rural

\*\*>2,000 and <10,000 inhabitants: **semi-urban** 

\*\*\* > 10,000 inhabitants: urban









| Cluster1    | Cluster 2        | Cluster 3        | Cluster 4  | Cluster 5        |
|-------------|------------------|------------------|------------|------------------|
| Urban***    | Semi-<br>urban** | Semi-<br>urban** | Urban***   | Semi-<br>urban** |
| Age 65-74   | Age >75          | Age 50-64        | Age 65-74  | Age >75          |
| High income | Low income       | Low income       | Low income | Low<br>income    |
| Male        | Male             | Male             | Male       | Male             |
| Non-smoker  | Non-smoker       | Non-smoker       | Non-smoker | Non-<br>smoker   |
| Obesity     | Obesity          | Overweight       | Obesity    | Overweight       |
| Alive       | Alive            | Alive            | Alive      | Death            |
| Stage II    | Stage II         | Stage 0          | Stage III  | Stage III        |

\*< 2,000 inhabitants: rural

\*\*>2,000 and <10,000 inhabitants: **semi-urban** 

\*\*\* > 10,000 inhabitants: urban





Paper IV Context



1. Cancer survival trends are generally increasing. One medical consequence is an increased of subsequent diagnosis with another cancer.

2. Such risk factors as obesity, smoking or heavy alcohol use could be determinant in developing a subsequent primary cancer (SPC).

3. To analyze the association between smoking and heavy drinking and the risk of SPC in Lleida.

### Salut/GS Gestió de Serveis Sanitaris













|             | Total |      | SPC | sa              |            |           |   |                 | <b>T</b> . 1 |      | CDC | 3              | 1          |           |
|-------------|-------|------|-----|-----------------|------------|-----------|---|-----------------|--------------|------|-----|----------------|------------|-----------|
|             | (DV)  | %    | n   | % (n/py) * 100  | Crude HR   | 95% CI    | 1 |                 | lotal        |      | SPC | Sa             |            |           |
| <b>C</b> 1  | (93)  | 70   |     | 70 (II/ Py) 100 | crude mit  | 3370 CI   | - |                 | (py)         | %    | n   | % (n/py) * 100 | Crude HR   | 95% CI    |
| Gender      |       |      |     |                 |            |           |   | Body mass index |              |      |     |                |            |           |
| Female      | 4,349 | 42.6 | 69  | 1.6             | Ref. group | -         |   | Normal weight   | 2,781        | 26.3 | 63  | 2.3            | Ref. group | -         |
| Male        | 6,208 | 58.4 | 165 | 2.7             | 1.7        | 1.3 - 2.2 |   | Overweight      | 4,616        | 43.7 | 108 | 2.3            | 1.0        | 0.7 - 1.4 |
| Age         |       |      |     |                 |            |           |   | Obese           | 3,160        | 29.9 | 63  | 2.0            | 0.9        | 0.6 - 1.3 |
| 50-59       | 2,195 | 20.8 | 30  | 1.4             | Ref. group | 123       |   | Smoking         |              |      |     |                |            |           |
| 60-69       | 3,415 | 32.3 | 79  | 2.3             | 1.7        | 1.1 - 2.6 |   | No              | 7,462        | 70.7 | 146 | 2.0            | Ref. group | -         |
| 70-79       | 3,416 | 32.4 | 102 | 3.0             | 2.1        | 1.5 - 3.3 |   | Yes             | 3,095        | 29.3 | 88  | 2.8            | 1.5        | 1.1 - 1.9 |
| 80-         | 1,531 | 14.5 | 24  | 1.6             | 1.1        | 0.6 - 2.0 |   | Diabetes        |              |      |     |                |            |           |
| Cancer type |       |      |     |                 |            |           |   | No              | 10,162       | 96.3 | 224 | 2.2            | Ref. group | 1-1       |
| Type 3      | 323   | 3.1  | 4   | 1.2             | Ref. group | -         |   | Yes             | 395          | 3.7  | 10  | 2.5            | 1.2        | 0.6 - 2.2 |
| Type 2      | 2,584 | 23.4 | 29  | 1.1             | 0.9        | 0.3 - 2.6 |   | Heavy drinking  |              |      |     |                |            |           |
| Type 1      | 2,119 | 21.2 | 66  | 3.0             | 2.4        | 0.9 - 6.7 | 1 | No              | 10,404       | 98.6 | 225 | 2.2            | Ref. group | -         |
| Type 0      | 5,524 | 52.3 | 135 | 2.4             | 2.0        | 0.7 - 5.4 |   | Yes             | 153          | 1.4  | 9   | 5.9            | 2.7        | 1.4 - 5.4 |







|                | Hazard ratio | 95% Cl a   |
|----------------|--------------|------------|
| Female         | 1.0          | Ref. group |
| Male           | 1.4          | 1.1 - 1.9  |
| Age 50-59      | 1.0          | Ref. group |
| Age 60-69      | 1.6          | 1.1 - 2.5  |
| Age 70-79      | 2.2          | 1.5 - 3.4  |
| Age 80-        | 1.2          | 0.7 - 2.0  |
| Smoking        | 1.3          | 1.0 - 1.7  |
| Heavy drinking | 2.4          | 1.3 - 4.8  |
|                |              |            |







|                | Males                    |                     | Females     |            |
|----------------|--------------------------|---------------------|-------------|------------|
|                | Adjusted HR <sup>a</sup> | 95% Cl <sup>b</sup> | Adjusted HR | 95% Cl     |
| Age 50-59      | 1.0                      | Ref. group          | 1.0         | Ref. group |
| Age 60-69      | 1.6                      | 1.0 - 2.7           | 1.8         | 0.8 - 3.9  |
| Age 70-79      | 2.0                      | 1.3 - 3.4           | 2.6         | 1.2 - 5.7  |
| Age 80-        | 0.5                      | 0.2 - 1.2           | 3.0         | 1.3 - 7.1  |
| Diabetes       | 1.4                      | 07-2.8              | -           | -          |
| Smoking        | 1.2                      | 1.0 - 1.6           | 1.8         | 0.8 - 3.7  |
| Heavy drinking | 2.3                      | 1.1 - 4.7           | 3.2         | 0.4 - 23.6 |
|                |                          |                     |             |            |







- Approximately 1.8 million new colorectal cancer cases were diagnosed worldwide.
- Between 350 and 400 new cases in Lleida were diagnosed each year.
- Some studies estimate that 30-50 % of colorectal cases could be avoided<sup>1</sup>.
- Aspirin has long been known to prevent cardiovascular and cerebrovascular.



■GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022 Aug 20;400(10352):563-591.

### Salut/GS Gestió de Serveis Sanitaris





#### Study population **Risk factors Statistics** and aspirin use • Body Mass Index (BMI): 18.5-· Colorectal cancer cases diagnosed · Cox 25-29.9 24.9 normal weight, between 2012 and 2016 proportional overweight and >30 obese. hazard model $\cdot$ Inhabitants from Lleida region aged > • **Smoking:** at least 5 years previous Hazard ratios cancer diagnosis 50 years and 95% $\cdot$ Aspirin exposition during, at least, 5 Confidence • **Heavy drinking:** >40 grams/day in years. Intervals men and >24 grams/day in women for $\cdot$ Aspirin use > 75 mg/daily 1 or more years

















|                 | Total                |      |      |           | <b>C</b> 1      |            |  |
|-----------------|----------------------|------|------|-----------|-----------------|------------|--|
|                 | Person-Year<br>(p-y) | %    | n    | % (n/p-y) | HR <sup>1</sup> | 95% CI     |  |
| Gender          |                      |      |      |           |                 |            |  |
| Female          | 639,455              | 53.1 | 485  | 0.8       | 1.0             | Ref. group |  |
| Male            | 563,716              | 46.9 | 791  | 1.4       | 1.9             | 1.6-2.1    |  |
| Age             |                      |      |      |           |                 |            |  |
| (50-59)         | 393,275              | 32.7 | 303  | 0.8       | 1.0             | Ref. group |  |
| (60-69)         | 297,538              | 24.7 | 426  | 1.4       | 1.8             | 1.6-2.1    |  |
| (70-79)         | 215,272              | 17.9 | 349  | 1.6       | 2.0             | 1.9-2.6    |  |
| (80-89)         | 147,817              | 12.3 | 184  | 1.2       | 1.6             | 1.3-1.9    |  |
| (90–)           | 149,269              | 12.4 | 14   | 0.1       | 0.1             | 0.1 - 0.2  |  |
| Aspirin         |                      |      |      |           |                 |            |  |
| Non-use         | 1,068,470            | 88.8 | 1138 | 1.2       | 1.0             | Ref. group |  |
| Use             | 134,701              | 11.2 | 138  | 1.0       | 0.9             | 0.8-1.1    |  |
| Body mass index |                      |      |      |           |                 |            |  |
| Normal weight   | 350.994              | 29.2 | 169  | 0.5       | 1.0             | Ref. Group |  |
| Overweight      | 404.905              | 33.7 | 504  | 1.2       | 2.5             | 2.2-3.1    |  |
| Obesity         | 447,272              | 37.2 | 603  | 1.3       | 2.7             | 2.3-3.3    |  |
| Risky drinking  |                      |      |      |           |                 |            |  |
| No              | 1,177,736            | 97.9 | 1220 | 1.0       | 1.0             | Ref. Group |  |
| Yes             | 25,435               | 2.1  | 56   | 2.2       | 2.1             | 1.6–2.7    |  |
| Smoking         |                      |      |      |           |                 |            |  |
| No              | 1,094,891            | 91.0 | 1056 | 1.0       | 1.0             | Ref. Group |  |
| Yes             | 108,280              | 9.0  | 220  | 2.0       | 2.0             | 1.8–2.4    |  |

<sup>1</sup> Hazard ratio.







|                | Adjusted Hazard Ratio<br>(aHR); 95% CI <sup>1</sup> | <i>p</i> -Value |  |
|----------------|---|-----------------|--|
| Female         | -   | Ref. Group      |  |
| Male           | 1.8 (1.6–2.1)                                       | < 0.001         |  |
| (50-59)        | -   | Ref. Group      |  |
| (60–69)        | 1.8 (1.6–2.1)                                       | < 0.001         |  |
| (70–79)        | 2.3 (1.9–2.7)                                       | < 0.001         |  |
| (80-89)        | 2.2 (1.8–2.6)                                       | 0.007           |  |
| (90-)          | 0.2 (0.1–0.3)                                       | < 0.001         |  |
| Aspirin use    | 0.7 (0.6–0.8)                                       | 0.006           |  |
| Normal weight  | -   | Ref. Group      |  |
| Overweight     | 1.4 (1.2–1.7)                                       | < 0.001         |  |
| Obesity        | 1.5 (1.3–1.8)                                       | < 0.001         |  |
| Risky drinking | 1.6 (1.2–2.0)                                       | 0.006           |  |
| Smoking        | 1.4 (1.3–1.7)                                       | < 0.001         |  |

<sup>1</sup> Confidence interval.







|                | Me   | en                      | Women  |                         |  |
|----------------|--|-------------------------|--|-------------------------|--|
|                | Adjusted<br>Hazard Ratio<br>(aHR); 95% CI <sup>1</sup> | <i>p-</i> Value         | Adjusted<br>Hazard Ratio<br>(aHR); 95% CI <sup>1</sup> | <i>p</i> -Value         |  |
| (50–59)        | -  | Ref. Group              | Ξ  | Ref. Group <sup>2</sup> |  |
| (60-69)        | 1.9 (1.7-2.3)  | < 0.001                 | 1.7 (1.3-2.2)  | < 0.001                 |  |
| (70-79)        | 2.3 (1.9-2.8)  | < 0.001                 | 2.3 (1.7-2.9)  | < 0.001                 |  |
| (80-89)        | 2.1 (1.6-2.7)  | < 0.001                 | 2.2 (1.7-3.0)  | < 0.001                 |  |
| (90–)          | 0.2 (0.1-0.4)  | < 0.001                 | 0.2 (0.1-0.5)  | < 0.001                 |  |
| Aspirin use    | 0.7 (0.6-0.9)  | 0.005                   | 0.6 (0.4–0.8)  | 0.005                   |  |
| Normal weight  | -  | Ref. Group <sup>2</sup> | -  | Ref. Group <sup>2</sup> |  |
| Overweight     | 1.5 (1.2-2.0)  | < 0.001                 | 1.2 (0.9–1.6)  | 0.1                     |  |
| Obesity        | 1.6 (1.3-2.1)  | < 0.001                 | 1.4 (1.2–1.9)  | 0.004                   |  |
| Risky drinking | 1.6 (1.2-2.1)  | 0.001                   | 1.2 (0.4-3.7)  | 0.7                     |  |
| Smoking        | 1.5 (1.3–1.7)  | <0.001                  | 1.4 (0.9–2.2)  | 0.1                     |  |

<sup>1</sup> Confidence interval. <sup>2</sup> Reference group.





- Nowadays, cancers such as pancreatic or lung are the highest mortal.
- Some studies suggest that aspirin decreased the risk of some types of cancer<sup>1</sup>.
- Exist controversies against the protective effect of aspirin on some cancers.



<sup>1</sup>Tsoi K *et al*. Long-tearm use of low-dose aspirin for cancer prevention: A 10-year population cohort study in Hong Kong. International Journal of Cancer. 2019; 145 (267).

Paper VI

### Salut/(S) Gestió de Serveis Sanitaris













## Relative risk

|                      | Cancer Incidence     |                |                                   |                                      |  |
|----------------------|----------------------|----------------|-----------------------------------|--------------------------------------|--|
| Cancers              | Total n= 154,715 (%) | Aspirin group  | Non-aspirin group n = 138,117 (%) | Relative risk (95% Cl <sup>a</sup> ) |  |
|                      |                      | n = 16,598 (%) |                                   |                                      |  |
| Oesophagus           | 32 (0.02)            | 3 (0.02)       | 29 (0.03)                         | 0.86 (0.26 - 2.82)                   |  |
| Stomach              | 135 (0.09)           | 18 (0.11)      | 117 (0.08)                        | 1.28 (0.78 – 2.1)                    |  |
| Colorectal           | 1,276 (0.82)         | 138 (0.83)     | 1,138 (0.82)                      | 1.01 (0.8 - 1.2)                     |  |
| Liver                | 60 (0.04)            | 7 (0.04)       | 53 (0.04)                         | 1.09 (0.5 – 2.42)                    |  |
| Pancreas             | 97 (0.06)            | 8 (0.05)       | 89 (0.06)                         | 0.63 (0.31 – 1.31)                   |  |
| Lung and bronchus    | 426 (0.28)           | 61 (0.37)      | 365 (0.26)                        | 1.39 (1.06 – 1.82)                   |  |
| Leukaemia            | 328 (0.21)           | 56 (0.34)      | 272 (0.20)                        | 1.71 (1.28 – 2.28)                   |  |
| Breast (female only) | 737 (0.48)           | 56 (0.34)      | 681 (0.49)                        | 0.77 (0.58 – 1.02)                   |  |
| Prostate (male only) | 916 (0.59)           | 113 (0.78)     | 803 (0.58)                        | 1.0 (0.82 – 1.23)                    |  |
| Bladder              | 567 (0.37)           | 100 (0.60)     | 467 (0.34)                        | 1.78 (1.43 – 2.21)                   |  |
| Lymphoma             | 131 (0.08)           | 8 (0.05)       | 123 (0.09)                        | 0.54 (0.26 - 1.11)                   |  |









\*A Cox regression was calculated for each cancer









MCA and K-means are used for exploring large databases without preexisting hypotheses. However, in cancer epidemiology is typically hypotheses-driven.



The shorter follow-up did not allow for more Secondary Primary Cancers to be observed. A longer observation period would improve the quality of the sample.



Aspirin can be purchased directly from pharmacies without a doctor's prescription. The results are consistent with previous literature.



Risk factors data comes from clinical records and may be underreported.









The cloud applications offer accessibility and variability that are crucial to add qualified knowledge from data to medical experts.















Multiple Correspondence Analysis (MCA) is an ideal algorithm to analyze associations between cancer and some factors.











- •... Multiple Correspondence Analysis (MCA) is an ideal algorithm to analyze associations between cancer and some factors.



MCA and K-means is a perfect alliance for detecting patterns and associations of cancer from information about patients and risk factors.









The significance of PBCR for monitoring and analyzing cancer and their potential research when integrated with other databases, such as risk factors or medication exposures.













The significance of PBCR for monitoring and analyzing cancer and their potential research when integrated with other databases, such as risk factors or medication exposures.



Smoking and heavy alcohol use increase the risk of SPC during the first follow-up years, especially among men.











The significance of PBCR for monitoring and analyzing cancer and their potential research when integrated with other databases, such as risk factors or medication exposures.



Smoking and heavy alcohol use increase the risk of SPC during the first follow-up years, especially among men.



Aspirin use decreases the risk of colorectal cancer and overweight,
smoking and heavy drinking increase this risk. Aspirin also decreases the risk of pancreatic, prostate cancer and lymphoma.









### Data warehouse

Add external databases



**Future work** 





### Data warehouse

Add external databases

# Data Analysis

Extend similar studies with other types of cancer



**Future work** 





### Data warehouse

Add external databases

# Data Analysis

Extend similar studies with other types of cancer

### Cancer prediction

Train and deploy supervised algorithms to predict cancer



**Future work** 





### Data warehouse

Add external databases

# Data Analysis

Extend similar studies with other types of cancer

### Cancer prediction

Train and deploy supervised algorithms to predict cancer

## Decision Support System

Integration to other population cancer registries









In eHealth, quality is more important than quantity. This drives the innovation in the healthcare industry.







# Machine Learning Approaches for Comprehensive Analysis of Population Cancer Registry Data



**Ph.D Defense** 

Authored by Dídac Florensa Cazorla

Supervised by Pere Godoy Garcia Francesc Solsona Tehàs Jordi Mateo Fornés

Industrial supervision by Miquel Mesas Julió

19th April 2023